PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11265773-3	2001	The authors designed the current study to determine whether the histone deacetylase inhibitor, depsipeptide FR901228 (DP), could enhance NY-ESO-1 induction mediated by the DNA demethylating agent 5-Aza-2"-deoxycytidine (DAC) in cell lines established primarily from thoracic cancers.	Depsipeptides	95-107	cancer/testis antigen 1A	Homo sapiens	137-145	
18677478-6	2009	Induction of NY-ESO-1 expression on tumor targets using the demethylating agent 5-aza-2"-deoxycytidine (alone or in combination with the histone deacetylase inhibitor depsipeptide) resulted in enhanced interferon-gamma secretion by the TCR-transduced PBL on culture with treated targets.	Depsipeptides	167-179	cancer/testis antigen 1A	Homo sapiens	13-21	
16140944-6	2005	Quantitative reverse transcription-PCR analysis revealed robust, coincident induction of BORIS and NY-ESO-1 expression in lung cancer cells, but not normal human bronchial epithelial cells following 5-aza-2"-deoxycytidine (5-azadC), Depsipeptide FK228 (DP), or sequential 5-azadC/DP exposure under clinically relevant conditions.	Depsipeptides	233-245	cancer/testis antigen 1A	Homo sapiens	99-107